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Abstract 
NSF has been reported to be associated with the administration of gadolinium based contrast 
agents in patients with severely impaired renal function (SIRF), end stage renal disease (ESRD) 
or acute renal failure (ARF). Since the vast majority of these patients do not get NSF, it is highly 
likely that patient factors play a role in its development.  Although “free" or dechelated Gd3+ is 
thought by some to be the only trigger of NSF, recent evidence suggests that chelated-Gd3+ may 
be important. Chelated-Gd3+ Omniscan (Gadodiamide) and Magnevist (Gadopentetate) can 
directly stimulate macrophages and monocytes to release profibrotic cytokines and growth 
factors capable of initiating and supporting the tissue fibrosis that is characteristic of NSF. In 
addition, an effect of chelated-Gd3+ on Fibroblasts has also been demonstrated. Chelated-Gd3+ in 
the form of Omniscan, Magnevist, Multihance, and Prohance increased proliferation of human 
dermal fibroblasts. Indeed increased numbers of Macrophages, together with activated 
Fibroblasts and Fibrocytes are essential cells in the fibrotic process and are present in NSF skin. 
Accordingly it is important that chelated-Gd3+, in combination with patient cofactors, is 
considered in the aetiology of NSF associated with enhanced scans.  
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Nephrogenic systemic fibrosis (NSF) is a rare, but potentially serious, acquired systemic disease 
initially described as a form of scleromyxedema (1).  To date, it has only been reported in 
patients with severely impaired renal function (SIRF), end stage renal disease (ESRD) and those 
in acute renal failure (ARF) (2, 3, 4, 5).  The many risk factors shown to be associated with NSF 
include: oedema (6), metabolic acidosis, thrombotic events, high dose erythropoietin (EPO) (7, 
8), systemic inflammation (9), recent surgery, kidney disease (10) and Gadolinium (Gd3+) Based 
Contrast Agent (GBCA) exposure (11, 12) especially when used at relatively high dose GBCA 
(13, 5).  One current hypothesis assumes that the increased retention of GBCA, brought about by 
SIRF and ESRD, leads to the increased Gd3+ release from GBCA.  This “Free" or dechelated 
Gd3+ is then postulated to trigger NSF (14).  Although there is no evidence that inorganic Gd3+-
species directly trigger NSF, the hypothesis that dechelated inorganic Gd3+ might cause NSF is 
based on the following rationale: 
 
1. The elimination half-life of gadolinium chelates increases in normal human volunteers from 
1.5 hours to over 30 hours in patients with renal insufficiency (15, 16, 17, 18).   
2. Differences in in vitro stability constants control the rate and extent of Gd3+ release (14). 
3. Released Gadolinium precipitates and is phagocytosed by tissue macrophages and Gd3+ has 
been identified in the skin of affected patients (19, 20). 
4. The phagocytosis of Gadolinium triggers inflammatory and fibrotic responses at the site of 
precipitation.  
5. Detection of Gadolinium deposits in NSF tissue. 
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These ideas, coupled with in vitro stability constant parameters, have led investigators to propose 
that “free” gadolinium liberated from the chelate is the culprit species in NSF-associated with 
enhanced scans.   There are several published studies that have assessed the different 
stability constants of GBCAs using a number of in vitro and in vivo assays and, depending on the 
experimental conditions and methods of gadolinium detection, these have shown great variation 
in both absolute values, and in relation to each other (21).  It can be argued that these, and a 
number of other potential hypotheses based on comparative stability, have arisen, at least in part, 
in order to explain the difference in reported NSF case numbers between GBCA, such that agents 
with lower in vitro stability are more likely to trigger NSF.  However this theory does not take 
into account other factors which can explain the differences in reported numbers and is largely 
based on thermodynamic stability (Ktherm), a measurement made at pH 11, which does not reflect 
physiological conditions (see Table 1).   
 
When taken together these data do not provide a cause and effect relationship in vivo.   
Furthermore, the observations that only a small minority of ESRD patients develop NSF (2, 5) 
clearly indicate that other associated factors play a significant role in the development of NSF:   
 
 Gadolinium is usually, but not always found in NSF patient biopsies (20). 
 Some countries have a relatively high incidence of NSF (23), while others using the same 
agent at standard dose have few reported cases (22). 
 Although there are clear differences in Ktherm between certain agents, stability constants are 
more similar when the constant reflects a more physiological environment (24, 25).  Table 2 
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shows the conditional stability constants (Kcond), which reflect the calculated stability at a pH 
of 7.4. 
 
NSF, which was first recognized by Cowper (1) and linked to GBCA in 2006 (24), is 
characterized by induration, thickening and tightening of the skin.  Distal parts of the body are 
usually most affected (26) but the trunk as well as internal organs such as the lungs, heart, liver, 
kidneys, skeletal muscle and diaphragm can also develop lesions.   Histopathologically, NSF is 
characterized in early stages by the presence of dermal collagen interspersed with fluid oedema, 
mucin and elastin (27).   Fibocytes or “spindle” cells are abundant and very closely associated 
with the developing fibrosis.  Fibrocytes are a new class of bone marrow derived leukocyte 
subpopulation which display a distinctive phenotype with surface expression of procollagen, 
vimentin and CD34 and are capable of specifically entering and localizing to tissue injury sites 
(28). 
 
Although fibrocytes are thought to account for as many as 10% of cells that are recruited to sites 
of acute tissue injury (28) it is not known whether these cells initiate or support the development 
of the fibrotic lesions associated with NSF.  However the fact that fibrocytes possess the ability 
endocytose material in their surroundings has been proposed as a mechanism for their 
involvement in NSF (29).  Indeed, whilst an initiator role for the fibrocyte is uncertain, it is likely 
that its involvement increases as disease develops.  Although both CD34 and procollagen I are 
key markers of fibrocytes, collagen and procollagen I positivity are low in early stages.  As 
disease develops, extracellular collagen deposition appears to correlate with increases in the 
procollagen I positivity of fibrocytes (27).       
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Fibroblasts however, being resident interstitial cells, regulate responses to local foreign material 
and are thus likely to initiate any response to high level exposure of GBCA in the oedematous 
periphery.  Indeed fibroblasts are also present in early NSF disease and numbers increase 
steadily with lesion age (30).  α-Smooth muscle actin (α-SMA) positive myofibroblasts, or 
“activated” fibroblasts, become increasingly frequent and florid as lesions develop, to the extent 
that lesions resemble a site of acute tissue injury.  Myofibroblasts are abundant in the deep 
dermis and around subcutaneous tissues, colocalising exactly with developing fibrosis (1, 30).  In 
fact areas rich in activated fibroblasts stain very strongly with Alcian blue which indicate 
elevated deposition of hyaluronan and sulfated glycosaminoglycans (31).  Such data strongly 
implicate fibroblasts as effector cells in the development of NSF. 
 
Macrophages are also present in NSF tissue (30, 32).   Increased numbers of macrophages, 
increased expression of Factor XIIIa+ and TGFβ1, together with the activated fibroblasts and 
infiltrated fibrocytes are present in dermal and sub-dermal skin.  These can also extend into the 
muscles along tracts of fibrotic tissue and cause a severe infiltrative myopathy in NSF patients 
(33).  Since it has already been established that CD68+/factor XIIIa+ dendritic cells and TGFβ1 
orchestrate the host response to eliminate noxious putative etiologic agents, it is likely that these 
factors have this role in NSF (32).  The high levels of TGFβ1 expression and its role in the 
regulation of dendritic cell maturation (34, 35) suggest at least one mechanism that may promote 
lesion formation in NSF (32).   
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Gd3+-species have also been found in NSF tissue co-localised in areas of dermal inflammation 
rich in macrophages.  In freshly cut paraffin block surfaces gadolinium was detected ranging 
from 1 to 2270 cps/mm2 in 57 cutaneous biopsies of NSF. Gd was associated with P, Ca, and 
usually Na in tissue deposits (19).   High et al. analyzed thirteen affected skin samples from 
seven patients (20).  Gadolinium had been deposited in four of thirteen samples (four of the 
seven patients with NSF) at an average concentration of 70 ppm.  A sample of uninvolved skin 
(with actinic keratosis) from a patient with NSF had a gadolinium concentration of only 5 ppm.  
High et al (20) detected insoluble Gd3+-species of <1µm in diameter confined to areas of fibrosis 
in NSF tissue.  Since Gd3+-species was considered to be intracellularly located, possibly within 
lysosomes, it was proposed that NSF was caused by precipitated Gd3+-species being 
phagocytosed by macrophages which in turn produce and secrete the cytokines and growth 
factors that stimulate fibrosis (20).   
 
Whilst the observations by Thakral, Abraham and High are extremely important in our 
understanding of the disease, the reasoning currently offered to explain the presence of Gd3+-
species in NSF tissue may not necessarily be correct.  The basis for this assumption is that “free” 
Gd3+, which can be toxic to cells, is suspected to be the causative agent.  Indeed the toxicity of 
Gd3+ necessitated chelation so that it could be safely used as an MR imaging agent.  Chelation 
both shields the body from damage and promotes GBCA rapid elimination.  However, there is 
now emerging alternative evidence to suggest that even chelated-Gd3+ has the ability to initiate 
cellular processes that were previously attributed to precipitated Gd3+ alone.   
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It has now been shown that chelated-Gd3+ (Gadodiamide (Gd3+-DTPA-BMA, Omniscan) and 
Gadopentetate dimeglumine (Gd3+-DTPA, Magnevist)) can directly stimulate human monocytes 
and macrophages to release profibrotic cytokines and growth factors capable of initiating and 
supporting the tissue fibrosis that is characteristic of NSF (36).    In these studies human 
peripheral blood monocytes were exposed to varying concentrations of GBCA and GdCl3.  
Changes in expression levels of relevant cytokines and growth factors were assessed by real-time 
polymerase chain reaction (rt PCR) of RNA isolated from peripheral blood monocytes and by 
quantitative assessment of numerous cytokines, growth factors, and other inflammatory 
mediators employing Searchlight ELISA of culture media.   Not surprisingly GdCl3 was shown 
to activate the expression of IL-6, IL-13, TGF-β and VEGF mRNA by normal human peripheral 
blood monocytes.  However, what was unexpected was the activation of cytokine release by 
Gadodiamide and Gadopentetate dimeglumine.  Cytokine levels assayed in culture supernatants 
from the treated cells by Searchlight ELISA confirmed the increased secretion of profibrotic 
cytokines and growth factors to chelated-Gd3+.   Such studies provide a direct mechanistic link 
with the histopathological findings of Thakral and Abraham (19) and High (20). 
 
In a series of follow-up studies Del Galdo (37) exposed terminally differentiated human 
peripheral blood macrophages to either Omniscan or saline before isolating and analysing 
cellular RNA for global gene expression microarray analysis.  Volcano plot analysis of the 
microarray data revealed that 31 genes were up-regulated by more than two-fold in the Omniscan 
treated macrophages (p<0.05).  Pathway analysis and rt PCR validation of the up-regulated genes 
strongly suggested the participation of Toll-Like Receptor (TLR) mediated activation and 
immunofluorescence analysis of activated cells demonstrated NFκB translocation from the 
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cytosol to the nucleus within minutes of GBCA application.  Indeed 5 out of 9 genes were 
chemokine genes from the CC and the CXC families.  ELISA of culture supernatants from 
cultured macrophages exposed to Omniscan indicated that CCL2, CCL8, CXCL10 and CXCL11 
were up-regulated between 10 and 240 fold higher than saline controls.  Correspondingly, 
immunofluorescence analysis of NSF skin biopsies revealed that CCL8 (MCP-2) was 
preferentially up-regulated compared to normal skin.   Such observations support the mechanistic 
relevance of the in vitro studies.   
 
Similarly, a direct effect of chelated-Gd3+ has also been demonstrated on fibroblasts in vitro.  In 
a study by Edward (38), gadodiamide added to culture medium, stimulated fibroblast growth. In 
the same study, fibroblasts exposed to gadodiamide synthesized increased levels of hyaluronan. 
NSF Fibroblasts cultured from the lesions of six NSF patients, all of whom were exposed to 
gadodiamide, synthesized excess levels of hyaluronan and collagen compared to control 
fibroblasts.  In a separate study (39) chelated-Gd3+ in the form of Omniscan, Magnevist, 
Multihance, and Prohance all increased proliferation of human dermal fibroblasts in monolayer 
culture.  Additionally, increased proliferation of cells was accompanied by an increase in 
production of Matrix Metalloproteinase-1 (MMP-1) and Tissue inhibitor of Matrix 
Metalloproteinase-1 (TIMP-1) but no increase in type I procollagen (39,40).  Specific analysis of 
the signaling events immediately after GBCA application shows activation of tyrosine kinases 
within minutes following GBCA exposure, again suggesting that chelated-Gd3+ could be acting 
as the trigger molecule (40). 
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Once again such studies provide a direct mechanistic link with the histopathological findings of 
Neudecker (31) and Jimenez (32) in NSF.  Perhaps as important, NSF patient serum stimulated 
control skin fibroblasts in vitro whilst healthy control serum was without effect (38).  This 
signifies that substances other than GBCA e.g. proinflammatory and or profibrotic cytokines, are 
secreted into serum by monocytes and or macrophages after GBCA exposure, and could control, 
participate or modulate the pathogenesis of NSF.   
 
These observations are extremely important since Wermuth (36) has demonstrated that 
conditioned media isolated from GBCA-exposed PBMC caused cultured human dermal 
fibroblasts to increase expression of extracellular matrix proteins and α-SMA indicating their 
conversion into myofibroblasts (36).  Since these studies show that it is possible for products of 
inflammatory cells to induce a fibrotic phenotype in normal dermal human fibroblasts in vitro, it 
is not inconceivable that GBCA, under certain conditions, could stimulate inflammatory cells to 
secrete the mediators essential to the development of NSF in vivo.  It is interesting to note that all 
but one of the six samples studied in the Edward experiments came from NSF patients with 
higher than normal levels of inflammatory cells; because of a pre-existing inflammatory 
condition at the time of their enhanced scans (38).   
 
This emerging evidence permits an alternative hypothesis (Figure 1): 
 
1. Protracted retention of GBCA in renal insufficiency provides the conditions for enhanced 
exposure of tissues to GBCA. 
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2. GBCA could themselves trigger inflammatory and fibrotic responses in the tissues of 
susceptible cells. 
3. GBCA interacting with cells may be internalised via receptor driven phagocytosis in 
macrophages and receptor mediated endocytosis in fibroblastic cells. 
4. The highly acidic environment inside lysosomes could provide the conditions for dechelation 
of GBCA. 
 
It is important to point out that receptor-mediated endocytosis of chelated Gd3+ has been 
proposed previously (41).  Franano observed acid dependent metabolism of chelated Gd3+ typical 
of lysosomal degradation at very low pH.  Thus it is possible that release of profibrotic cytokines 
precedes the lysosomal degradation of GBCA taken up by receptor-mediated endocytosis.  
Consequently the formation of tissue retained insoluble Gd3+-species may be secondary or a 
“footprint” of a receptor mediated cell response (Figure 2).  Such a mechanism is entirely 
consistent with the identification of Gd3+-species localised in areas of dermal inflammation rich 
in macrophages in NSF (19) and the detection of insoluble Gd3+-species of <1µm in diameter 
confined to areas of fibrosis in NSF tissue (20).    
 
Taken together the above data raise questions about the relevance of dechelated Gadolinium as a 
trigger in the development of NSF simply because chelated-Gd appears to be capable of 
stimulating the proinflammatory and profibrotic responses in cells that are able to perform 
endocytotic functions – fibrocytes, fibroblasts, macrophages and monocytes (Figure 1).  It was 
previously hypothesized that transmetallation, a process in which Gd3+ is displaced from the 
chelate complex, may drive Gd3+ accumulation in the tissues and, therefore provide the only 
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trigger for NSF.  However, since it has been shown that direct exposure of human fibroblasts, 
monocytes and macrophages to GBCA stimulates profibrotic and proinflammatory responses 
within minutes of exposure (37,40), so it is possible that chelated-Gd3+ is not as biologically inert 
as was previously thought.  Such data suggest that Gd-chelate could be a bioactive species 
associated with NSF in susceptible patients.  Such data raise questions about the roles of de-
chelated and retained gadolinium as trigger factors in the development of NSF.   Clearly such 
responses do not take place in every patient, thus some form of patient susceptibility is likely.  
Nevertheless, these data do help explain why cofactors such as high GBCA dose, SIRF and 
ESRD, dependent oedema and pre-existing inflammation might predispose patients receiving 
GBCA to develop NSF.  In this regard: 
 
 High single dose rather than repeated standard doses of GBCA carries the greatest risk in 
vivo (5, 11) accords with the concentrations of GBCA that are required to stimulate 
inflammatory cells and fibroblasts in vitro (36, 37, 38, 39, 40).   
 The increased exposure of interstitial tissue to GBCA brought about by the extended half life 
in ESRD and SIRF (2) accords with the effect of GBCA on macrophages and fibroblast 
inflammatory and fibrotic reactions in vitro (36, 37, 38, 39, 40).  
 The occurrence of NSF in temporal proximity to inflammatory and thrombotic episodes in 
affected patients (9, 42) suggests that macrophages and inflammatory cells may have been 
primed by these events and, thus, capable of an enhanced or exaggerated response to noxious 
agents accords with the observations that monocytes and macrophages can be directly 
stimulated by GBCA in vitro (36, 37). 
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 Dependent oedema / fluid overload leading to enhanced exposure of interstitial tissue to 
GBCA in vivo (6) accords with the observation that fibroblasts can elicit a profibrotic 
response in vitro (38, 39, 40).   
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Table 1: 
Thermodynamic Stability (Ktherm) constants of 5 GBCA. 
 
Dotarem 
Gadoterate 
meglumine 
ProHance 
Gadoteridol 
MultiHance 
Gadobenate 
dimeglumine 
Magnevist 
Gadopentetate 
dimeglumine 
Omniscan 
Gadodiamide 
Stability 
Log 
(Ktherm) 
25.4 22.8 22.6 22.1 16.8 
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Table 2: 
Conditional Stability (Kcond) constants of 5 GBCA. 
 
Dotarem 
Gadoterate 
meglumine 
ProHance 
Gadoteridol 
MultiHance 
Gadobenate 
dimeglumine 
Magnevist 
Gadopentetate 
dimeglumine 
Omniscan 
Gadodiamide 
Stability 
Log 
(Kcond) 
19.0 17.1 18.4 17.7 14.9 
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Figure 1: 
The following schematic of the proposed mechanism shows how the retention of chelated 
gadolinium, occurring after high dose, ESRD and pre-existing inflammation, might stimulate 
proinflammatory and profibrotic responses that are consistent with those seen in NSF.     
 
 
Figure 2: 
The following schematic suggests that the release of profibrotic cytokines following receptor 
mediated endocytosis of chelated gadolinium might precede and bring about the formation of 
tissue retained insoluble Gd3+ in NSF.  
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